2. UroToday Home
  3. Video Lectures

mHSPC Videos

Doublet Versus Triplet Intensification in Metastatic Hormone-Sensitive Prostate Cancer - Jacqueline Brown
Lutetium-177-PSMA-617 in First-Line mHSPC and Its Impact on PSA Depth, Undetectable Rates, and Time to Progression - Fred Saad
MEVPRO-3 Trial: Enzalutamide With or Without Mevrometostat in Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal
EMBARK Trial Data on Treatment Suspension in Non-Metastatic Prostate Cancer - Mika Matikainen
Debating Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer - Tyler Seibert
Q-TWIST Analysis Applied to ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer - Brigida Maiorano
Predicting Non-Cancer Mortality Risk in mHSPC Following Doublet Therapy Using STAMPEDE Data - Noel Clarke
Darolutamide Alone for Non-Metastatic CSPC: 52-Week Safety and Efficacy Results from the ARAMON Trial - Andrew Laccetti
Selecting Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Step Approach - Pedro Barata
How Clinicians Navigate Multidisciplinary Care for Metastatic Hormone-Sensitive Prostate Cancer - Jacqueline Brown
mHSPC Treatment Selection: ARPI Backbone, Biomarkers, and Docetaxel – Christopher Sweeney
Individualized Goals and Shared Decision-Making in mHSPC Care - Daniel George
Quality of Life and Treatment Intensification in mHSPC - Fred Saad
OPTIMAS Trial: Testing Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer - Umang Swami
Masofaniten Combined with Enzalutamide Investigated in Metastatic Hormone-Sensitive Prostate Cancer - Albert Jang
Selective PARP1 Inhibition Combined with ARPIs Under Investigation in the PETRANHA in mHSPC - Arun Azad
Longitudinal Analysis of Patient-Reported Outcomes in the PSMAddition Trial - Michael Morris
Practical Approaches to Genetic Testing in Metastatic Hormone-Sensitive Prostate Cancer - Emmanuel Antonarakis
How Patient Function and Independence Are Changing Advanced Prostate Cancer Care - Kristine Lacuna
Considerations for Managing Patients as They Progress to Castration-Resistant Prostate Cancer - Tian Zhang
Multidisciplinary Strategies for Managing the Complexities of mHSPC Care - Neal Shore
MEVPRO-3 Trial: Testing EZH2 Inhibition in First-Line Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal
A Multidisciplinary Approach to Supporting Patients with Metastatic Hormone-Sensitive Disease - Jack Andrews
ASPIRE Trial: Evaluating Docetaxel's Role in Metastatic Hormone-Sensitive Prostate Cancer - Deepak Kilari & Rana McKay
Prognostic Tool Evaluated For Early Treatment Decisions for Metastatic Hormone-Sensitive Prostate Cancer - Soumyajit Roy
PTEN Loss in mHSPC: Why It Changes How We Monitor and Treat Patients - Daniel George, Neal Shore, David Morris, & Neeraj Agarwal
PTEN Loss and the Future of Precision Treatment in mHSPC - Karim Fizazi & Noel Clarke
Association of PSA Trajectories with Survival in mHSPC from ARASENS and ARANOTE Trials - Christopher Wallis
Genomic Testing and the Evolving Role of PARP Inhibitors in Prostate Cancer - Tanya Dorff
Systematic Review Evaluates Radiologic Progression-Free Survival as a Surrogate for Overall Survival in mHSPC - Neal Shore & Alicia Morgans
Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko
Study on Metastatic Hormone-Sensitive Prostate Cancer Survival Trends - Neeraj Agarwal
Analysis of Patient-Reported Quality of Life from the AMPLITUDE Trial - Eleni Efstathiou
Following the AMPLITUDE Trial: Addressing Challenges and Implementing Biomarker Testing for mHSPC - Pedro Barata
A Real-World Study of mHSPC Patients: Comparative Survival with Apalutamide and Enzalutamide - Neal Shore
Real-World Overall Survival with Apalutamide Versus Abiraterone in mHSPC - Benjamin Lowentritt
Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa
Analysis of the Phase III CAPItello-281 Trial: Capivasertib plus Abiraterone in PTEN-Deficient mHSPC - Daniel George
Phase III CAPItello-281 Trial Results for mHSPC with PTEN Loss - Karim Fizazi
Real-World Study of Apalutamide and Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Mehmet Asim Bilen
CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George
Phase 2 EXTEND Trial of Metastasis-Directed Therapy with Continuous Hormone Therapy - Alexander Sherry & Bilal Siddiqui
Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial - Xiaolei Shi
Metastasis-Directed Therapy for Low-Volume mHSPC - Luis Salgado
Managing mHSPC with ADT and ARPI Therapy - Brian Chapin & David Morris
Treatment Sequencing and PARP Inhibitors in Advanced Prostate Cancer - Tanya Dorff
Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu
Analysis of Darolutamide Plus ADT in ARANOTE Trial for Metastatic Hormone-Sensitive Prostate Cancer - Gordon Brown
Metachronous mHSPC Treatment: Role of Darolutamide in Doublet Therapy - Jason Hafron
PSA Thresholds in mHSPC: What VA Data Reveals About Optimal Targets - Stephen Freedland
Darolutamide + ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer - Hanan Goldberg
HRR Gene Defects Predict Rapid Progression in mHSPC Patients - Elena Castro & David Olmos
Personalizing mHSPC Treatment: When to Add Chemotherapy to Darolutamide and ADT - Kristine Peregrino Lacuna
Darolutamide in mHSPC: ARANOTE Trial and Real-World Applications - Jacqueline Brown
Real-World VA Study Explores Use of ARPIs in Metastatic Hormone-Sensitive Prostate Cancer - Martin Schoen
TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Patients with Suboptimal PSA Response - Alexandra Sokolova
Exploring IGF-1 Pathway Biomarkers and Outcomes in Metastatic Hormone-Sensitive Prostate Cancer - Lisa Horvath
Optimal ARPI Selection in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study - Pedro Barata
AMPLITUDE Trial: Niraparib Delays Progression in HRR-Mutant Prostate Cancer - Gerhardt Attard
Subgroup Analysis Confirms Darolutamide Efficacy in Black Prostate Cancer Patients - Quoc-Dien Trinh
ARANOTE Trial Shows Benefit of Darolutamide in Low-Volume mHSPC - Fred Saad
Darolutamide Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Without Chemotherapy - Fred Saad
Optimal Treatment Strategies for De Novo Metastatic Hormone-Sensitive Prostate Cancer - Neal Shore
Selecting Patients for Triplet Therapy in Metastatic Prostate Cancer - Oliver Sartor
TRIPLE-SWITCH Trial: Intensifying Treatment for Suboptimal PSA Response in mHSPC - Michael Ong, Alexandra Sokolova & Tanya Dorff
Real-World Data Explores Benefits of Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan
FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer - Neal Shore
Personalizing mHSPC Treatment: Doublet Therapy for Elderly, Low-Volume Metastatic Prostate Cancer - Zachary Klaassen
Apalutamide vs Enzalutamide: Racial Disparities in mCSPC Treatment Outcomes - Benjamin Lowentritt
Treatment Options for De Novo Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal
HSPC to mCRPC: Management Current Approaches and Future Developments - Michael Cookson & Jason Efstathiou
Evolution of Chemohormonal Therapy for Metastatic Prostate Cancer - Pedro Barata
ARANOTE Study Shows Benefits of Deep PSA Response with Darolutamide - Neal Shore
Evolution of Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata
Optimizing Multidisciplinary Care for Metastatic Hormone-Sensitive Prostate Cancer - Zachary Klaassen
Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami
PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients - Hannah McManus
PSA Responses with Darolutamide Plus ADT in the ARANOTE Trial - Fred Saad
ARASENS Trial Analysis Investigates Impact of Initial PSA Values on Treatment Response in mHSPC - Alicia Morgans
LIBERTAS Clinical Trial Explores Treatment Optimization in mHSPC - Arun Azad
Investigating PARP Expression as Biomarker for Targeted Therapy in Prostate Cancer - Emmanuel Antonarakis
Examining Post-Prostatectomy Metastasis Patterns in Hormone-Sensitive Prostate Cancer - Nicolas Sayegh
Comparing ARPI Options Across Disease Volume and Metastatic Timing in mHSPC - Syed Arsalan Ahmed Naqvi & Irbaz Riaz
PERSIAN Trial Explores SBRT Benefits in Oligometastatic Hormone-Sensitive Prostate Cancer - Giulio Francolini
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
Tumor Suppressor Gene Status Refines Prognosis and Treatment Selection in Metastatic Prostate Cancer - Martino Pedrani
IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer - Stacy Loeb
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher
ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
ADT Remodels the Tumor Microenvironment from Immunologically Cold to Hot - Matthew Dallos
Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal
VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery
Introduction to mHSPC: Key Prognostic and Predictive Factors "Presentation" - Matthew Smith
Low-Volume mHSPC: When to Intensify Treatment "Presentation" - Robert Jones
In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor
Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James
Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas
In Which Patients with Metachronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Thomas Zilli
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal
Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin
How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf
Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney
Management of Frail Patients with mHSPC "Presentation" - Maria De Santis
Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"
Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis
Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
NCCN 2024 Prostate Cancer Guidelines Update: Relugolix Gains Prominence in Treating Metastatic Castration-Sensitive Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt
Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer
Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
Urology-Oncology Collaboration: Keys to Optimal Care in Metastatic Prostate Cancer - Damian Sorce & Manojkumar Bupathi
Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia
Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath
ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer - Michael Williams & Mark Fleming
LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad
Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell
Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt
Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein
Building an Integrated, Multidisciplinary Team to Optimize Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Chandler Park & Ryan Malone
Communication for Optimal Care in Patients Selected for Triplet Therapy Between Urology and Community Oncology - Vahan Kassabian & Sreekanth Reddy
Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu
ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard
The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong
Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone
Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer
Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad
Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Zachary Klaassen
Considerations for Integrating Triplet Therapy Into Clinical Practice - Evan Yu
Meta-Analysis Sheds Light on Optimal Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
Progress in Treating Metastatic Castration-Sensitive Prostate Cancer - Karim Fizazi
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan
Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard
Advancing Treatment for Metastatic Hormone-Sensitive Prostate Cancer: Insights from ARASENS Trial - Jan Philipp Radtke
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney
mHSPC: Low-Volume on Conventional vs High-Volume on Next-Gen Imaging – Treat as Low-Volume – Karim Fizazi
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
Darolutamide Approved for Patients with mHSPC - Charles Ryan
Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis
De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
Overall Survival With Stratification by Disease Volume and Metastatic Status – Analyses of the ARCHES Trial - Arun Azad
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo mCSPC – Karim Fizazi
Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak
The Upfront PSMA Study: Shifting Paradigms in Metastatic Hormone-Sensitive Disease - Declan Murphy & Arun Azad
Intensification of Hormonal Therapy for Men With Metachronous Metastatic Hormone-Sensitive Disease – Chris Sweeney
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer - Matthew Deek & Phuoc Tran
Standard of Care in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Michael Morris & Christopher Sweeney
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush
Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney
Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James
The Biology of Prostate Cancer - Kenneth Pienta
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal
Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke
First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin
Optimal Glucocorticoid Regimen with Abiraterone Acetate Presentation - Gert Attard
Follow Up of ADT Alone vs. ADT "Plus" Presentation - William Oh
Addition of AR Pathway Inhibitors vs. Docetaxel: Statisticians' Perspective Presentation - Matthew R Sydes
The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin
TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal
Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (ENZAMET) - Tanya Dorff
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin
Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney
ENZAMET Trial - Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer - Christopher Sweeney
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans
The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke
Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans
STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton